Delivery Order SPE2DB20D1100-SPE2DB24FC5P0

Award Date 7/2/24
Potential Completion Date 7/24/24
Potential Value $19K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) has awarded a Firm Fixed Price Delivery Order contract to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The contract, valued at $8,996.48, is for the supply of HYPERRAB 300 UNIT/ML VIAL 3ML, a medical product. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) worth up to $999,999,999.00 held by Amerisourcebergen with DLA Troop Support Medical, which serves as the primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,732.55 fixed-price delivery order is for the supply of HYPERRAB 300 UNIT/ML VIALML, a medical product. The contract has an ultimate completion date of April 21, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award is a $1,039.53 Firm Fixed Price Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of HYPERRAB 300 UNIT/ML VIALML, a medical product, with a completion date of February 25, 2025. The contract is not designated with a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,659.62 firm fixed-price delivery order is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product. The contract has a completion date of January 3, 2025 and was awarded on December 11, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product, to the U.S. Defense Logistics Agency (DLA). The firm-fixed-price, $9,391.75 contract has a completion date of July 1, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies to DLA facilities...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,744.80 firm fixed-price delivery order is for the medical product "HYPERRAB 300 UNIT/ML VIAL 5ML" and has an ultimate completion date of April 3, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that...
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was awarded a Firm Fixed Price delivery order contract valued at $1,116.57 by the Defense Logistics Agency (DLA) to provide HYPERRAB 300 UNIT/ML VIALML pharmaceuticals. This delivery order is part of a larger Indefinite Delivery Contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary...
This contract award to AmerisourceBergen Drug Corp's Corporate Office division is for the delivery of HYPERRAB 300 UNIT/ML VIALML, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The $7,443.80 firm fixed price contract has an ultimate completion date of August 29, 2024. The contract is a delivery order issued against a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued up to $999,999,999 through...
This is a firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $10,744.80, is for the procurement of HYPERRAB 300 UNIT/ML VIAL 5ML, a medical product. The contract has a period of performance through February 25, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML. The delivery order is valued at $3,756.72 and has a firm fixed-price pricing structure. The ultimate completion date for this contract is August 27, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
  • SPE2DB20D1100
    Indefinite Delivery Contract
  • SPE2DB20D1100-SPE2DB24FC5P0
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $18,783.50 to AmerisourceBergen Drug Corp's Corporate Office Division. The contract is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product, with a completion date of July 24, 2024. This contract is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract does not have a set-aside designation.

Generated 10/1/24, 12:05 PM